Wilmington Savings Fund Society FSB Buys Shares of 9,662 Organon & Co. (NYSE:OGN)

Wilmington Savings Fund Society FSB bought a new stake in Organon & Co. (NYSE:OGN) during the third quarter, Holdings Channel reports. The institutional investor bought 9,662 shares of the company’s stock, valued at approximately $185,000.

Other hedge funds have also made changes to their positions in the company. Prospera Private Wealth LLC acquired a new position in Organon & Co. in the 3rd quarter valued at approximately $25,000. William B. Walkup & Associates Inc. purchased a new position in shares of Organon & Co. during the 2nd quarter valued at $31,000. Abich Financial Wealth Management LLC increased its stake in shares of Organon & Co. by 5,646.3% in the third quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after acquiring an additional 2,315 shares during the last quarter. Atlas Capital Advisors LLC raised its holdings in shares of Organon & Co. by 2,236.5% during the second quarter. Atlas Capital Advisors LLC now owns 2,243 shares of the company’s stock worth $46,000 after acquiring an additional 2,147 shares in the last quarter. Finally, Trust Co. of Vermont boosted its position in Organon & Co. by 109.4% during the third quarter. Trust Co. of Vermont now owns 2,626 shares of the company’s stock valued at $50,000 after purchasing an additional 1,372 shares during the last quarter. 77.43% of the stock is owned by hedge funds and other institutional investors.

Organon & Co. Trading Down 1.8 %

Organon & Co. stock opened at $14.51 on Thursday. Organon & Co. has a one year low of $13.14 and a one year high of $23.10. The company’s fifty day moving average price is $16.25 and its two-hundred day moving average price is $19.05. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21. The company has a market capitalization of $3.74 billion, a price-to-earnings ratio of 2.88, a PEG ratio of 0.81 and a beta of 0.75.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the company posted $0.78 EPS. The business’s revenue was up 4.1% compared to the same quarter last year. On average, analysts forecast that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th were given a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.72%. The ex-dividend date of this dividend was Tuesday, November 12th. Organon & Co.’s dividend payout ratio is 22.22%.

Analyst Ratings Changes

Several brokerages have weighed in on OGN. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and raised their price objective for the company from $18.00 to $20.00 in a research report on Friday, September 6th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.